COL6A1 Promotes Metastasis and Predicts Poor Prognosis in Patients with Pancreatic Cancer

Overview

Journal Int J Oncol

Specialty Oncology

Date 2019 Jul 4

PMID 31268154

Citations 37

Authors

Kwabena Gyabaah Owusu-Ansah

GuangYuan Song

Ronggao Chen

Muhammad Ibrahim Alhadi Edoo

Jun Li

Bingjie Chen

Jian Wu

Lin Zhou

Haiyang Xie

Donghai Jiang

Shusen Zheng

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer is one of the most aggressive cancers worldwide with a high mortality rate. Prognosis remains poor even in this era of advanced medicine mainly due to early metastasis and invasion. The present study aimed to explore and validate predictors of distant metastasis and prognosis in pancreatic cancer. In our preliminary experiment, we established a novel metastatic pancreatic cancer cell line BxPC‑M8 from parent BxPC‑3 cells. Via whole genome sequencing, RT‑qPCR, western blotting, migration and invasion assays, we initially found that BxPC‑M8 shared similar biological characteristics to BxPC‑3, but only differed in enhanced metastatic and invasive capabilities with a significant increase in collagen type VI α1 chain (COL6A1) expression. Knockdown of COL6A1 via small interfering RNA led to a significant decrease in migration and invasion of BxPC‑M8 cells, suggesting suppressed epithelial‑mesenchymal transition. Furthermore, a significant increase in COL6A1 expression was observed in cancerous tissue compared with paracancerous tissue (40.7 vs 3.7, P=0.001). Additionally, its expression was observed to be significantly associated with distant metastasis and vascular invasion at the time of surgery. Multivariate analysis revealed that COL6A1 expression (hazard ratio 1.90, 95% confidence interval 1.04‑3.47, P=0.037) is an independent predictor of overall survival (OS). The median OS observed for COL6A1+ and COL6A1‑ patients was found to be 8±4 and 14±7 months (P=0.021), respectively. Of note, we identified that COL6A1 expression in tissue samples was associated with significantly reduced OS (P=0.001), demonstrating that COL6A1 may serve an important role in the metastatic process and could be considered as a predictor of poor outcomes in patients with pancreatic cancer. In addition, our findings suggest that COL6A1 could be an indicator of distant metastasis and a valid prognostic predictor in such patients; however, further investigation is required.

Citing Articles

Promotes Milk Production and Fat Synthesis Through the PI3K-Akt/Insulin/AMPK/PPAR Signaling Pathways in Dairy Cattle.

Han B, Lin S, Ye W, Chen A, Liu Y, Sun D Int J Mol Sci. 2025; 26(5).

PMID: 40076877 PMC: 11899919. DOI: 10.3390/ijms26052255.

COL6A1 Inhibits the Malignant Development of Bladder Cancer by Regulating FBN1.

Yang T, Peng X, Huang X, Cao P, Chen H Cell Biochem Biophys. 2024; .

PMID: 39365515 DOI: 10.1007/s12013-024-01573-6.

Enhancing Neoadjuvant Virotherapy's Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer.

Ferdous K, Tesfay M, Cios A, Shelton R, Hartupee C, Urbaniak A Biomedicines. 2024; 12(7).

PMID: 39062169 PMC: 11275208. DOI: 10.3390/biomedicines12071596.

Identification and validation of COL6A1 as a novel target for tumor electric field therapy in glioblastoma.

Chen J, Liu Y, Lan J, Liu H, Tang Q, Li Z CNS Neurosci Ther. 2024; 30(6):e14802.

PMID: 38887185 PMC: 11183175. DOI: 10.1111/cns.14802.

Identification and validation of a signature based on myofibroblastic cancer-associated fibroblast marker genes for predicting prognosis, immune infiltration, and therapeutic response in bladder cancer.

Qin R, Ma X, Pu S, Shen C, Hu D, Liu C Investig Clin Urol. 2024; 65(3):263-278.

PMID: 38714517 PMC: 11076800. DOI: 10.4111/icu.20230300.

References

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Tanaka T, Ikari K, Furushima K, Okada A, Tanaka H, Furukawa K . Genomewide linkage and linkage disequilibrium analyses identify COL6A1, on chromosome 21, as the locus for ossification of the posterior longitudinal ligament of the spine. Am J Hum Genet. 2003; 73(4):812-22. PMC: 1180604. DOI: 10.1086/378593. View

Jiang X, Tao H, Zou S . Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. Hepatobiliary Pancreat Dis Int. 2004; 3(3):464-8. View

Wang L, Yang G, Li H, Lu X . [The changing pancreatic cancer mortality in China (1991-2000)]. Zhonghua Nei Ke Za Zhi. 2005; 44(7):509-13. View

Fujita A, Sato J, Festa F, Gomes L, Oba-Shinjo S, Marie S . Identification of COL6A1 as a differentially expressed gene in human astrocytomas. Genet Mol Res. 2008; 7(2):371-8. DOI: 10.4238/vol7-2gmr432. View

Jones S, Zhang X, Parsons D, Cheng-Ho Lin J, Leary R, Angenendt P . Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008; 321(5897):1801-6. PMC: 2848990. DOI: 10.1126/science.1164368. View

Ponten F, Jirstrom K, Uhlen M . The Human Protein Atlas--a tool for pathology. J Pathol. 2008; 216(4):387-93. DOI: 10.1002/path.2440. View

Alkushi A . Validation of tissue microarray biomarker expression of breast carcinomas in Saudi women. Hematol Oncol Stem Cell Ther. 2010; 2(3):394-8. DOI: 10.1016/s1658-3876(09)50007-6. View

Chiu K, Chang Y, Wu Y, Lee S, Liao P . Quantitative secretome analysis reveals that COL6A1 is a metastasis-associated protein using stacking gel-aided purification combined with iTRAQ labeling. J Proteome Res. 2010; 10(3):1110-25. DOI: 10.1021/pr1008724. View

10.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

11.

Birnbaum D, Adelaide J, Mamessier E, Finetti P, Lagarde A, Monges G . Genome profiling of pancreatic adenocarcinoma. Genes Chromosomes Cancer. 2011; 50(6):456-65. DOI: 10.1002/gcc.20870. View

12.

Iacobuzio-Donahue C . Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project. Gut. 2011; 61(7):1085-94. PMC: 3356493. DOI: 10.1136/gut.2010.236026. View

13.

Qiu W, Su G . Challenges and advances in mouse modeling for human pancreatic tumorigenesis and metastasis. Cancer Metastasis Rev. 2012; 32(1-2):83-107. PMC: 3871863. DOI: 10.1007/s10555-012-9408-2. View

14.

Torres M, Rachagani S, Souchek J, Mallya K, Johansson S, Batra S . Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: applications in diagnosis and therapy. PLoS One. 2013; 8(11):e80580. PMC: 3835415. DOI: 10.1371/journal.pone.0080580. View

15.

Rhim A, Oberstein P, Thomas D, Mirek E, Palermo C, Sastra S . Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014; 25(6):735-47. PMC: 4096698. DOI: 10.1016/j.ccr.2014.04.021. View

16.

Hidalgo M, Cascinu S, Kleeff J, Labianca R, Lohr J, Neoptolemos J . Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology. 2014; 15(1):8-18. DOI: 10.1016/j.pan.2014.10.001. View

17.

Pan Y, Gao S, Hua Y, Liu L . Establishment of a pancreatic cancer stem cell model using the SW1990 human pancreatic cancer cell line in nude mice. Asian Pac J Cancer Prev. 2015; 16(2):437-42. DOI: 10.7314/apjcp.2015.16.2.437. View

18.

Zhu Y, Wan F, Shen Y, Wang H, Zhang G, Ye D . Reactive stroma component COL6A1 is upregulated in castration-resistant prostate cancer and promotes tumor growth. Oncotarget. 2015; 6(16):14488-96. PMC: 4546481. DOI: 10.18632/oncotarget.3697. View

19.

Whittle M, Izeradjene K, Rani P, Feng L, Carlson M, DelGiorno K . RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma. Cell. 2015; 161(6):1345-60. PMC: 4458240. DOI: 10.1016/j.cell.2015.04.048. View

20.

Escobar-Hoyos L, Shah R, Roa-Pena L, Vanner E, Najafian N, Banach A . Keratin-17 Promotes p27KIP1 Nuclear Export and Degradation and Offers Potential Prognostic Utility. Cancer Res. 2015; 75(17):3650-62. DOI: 10.1158/0008-5472.CAN-15-0293. View